Advanced Malignant Neoplasm

Oncology
9
Pipeline Programs
3
Companies
9
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
7
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 8 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Kura Oncology
Kura OncologySAN DIEGO, CA
2 programs
1
1
ZiftomenibPhase 1/2Small Molecule1 trial
KO-947Phase 11 trial
Active Trials
NCT03051035Terminated61Est. Jun 2020
NCT04067336Recruiting263Est. Oct 2028
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
QLF31907Phase 1/21 trial
Active Trials
NCT06394713Not Yet RecruitingEst. Dec 2026
CT
6 programs
6
TQB2103 for injectionPhase 11 trial
TQB2928 injectionPhase 11 trial
TQB3006 tabletsPhase 11 trial
TQB3015 tabletsPhase 11 trial
TQB3909 tabletsPhase 11 trial
+1 more programs
Active Trials
NCT05867563UnknownEst. May 2025
NCT06297642TerminatedEst. Jul 2024
NCT06344351CompletedEst. May 2025
+3 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Qilu PharmaceuticalQLF31907
Kura OncologyZiftomenib
Chia Tai TianQing Pharmaceutical GroupTQB2928 injection
Chia Tai TianQing Pharmaceutical GroupTQB3006 tablets
Chia Tai TianQing Pharmaceutical GroupTQB3015 tablets
Chia Tai TianQing Pharmaceutical GroupTQB3909 tablets
Chia Tai TianQing Pharmaceutical GroupTQB3912 tablets
Chia Tai TianQing Pharmaceutical GroupTQB2103 for injection
Kura OncologyKO-947

Clinical Trials (9)

Total enrollment: 324 patients across 9 trials

NCT06394713Qilu PharmaceuticalQLF31907

A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors

Start: Jun 2024Est. completion: Dec 2026
Phase 1/2Not Yet Recruiting
NCT04067336Kura OncologyZiftomenib

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Start: Sep 2019Est. completion: Oct 2028263 patients
Phase 1/2Recruiting
NCT06297642Chia Tai TianQing Pharmaceutical GroupTQB2928 injection

TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.

Start: May 2024Est. completion: Jul 2024
Phase 1Terminated
NCT06344351Chia Tai TianQing Pharmaceutical GroupTQB3006 tablets

A Clinical Trial of TQB3006 Tablets in Patients With Advanced Malignant Cancer

Start: Apr 2024Est. completion: May 2025
Phase 1Completed
NCT06165809Chia Tai TianQing Pharmaceutical GroupTQB3015 tablets

A Clinical Trial of TQB3015 Tablets in Patients With Advanced Malignant Cancer

Start: Dec 2023Est. completion: May 2024
Phase 1Withdrawn
NCT06165822Chia Tai TianQing Pharmaceutical GroupTQB3909 tablets

A Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets

Start: Dec 2023Est. completion: Mar 2024
Phase 1Unknown
NCT05997342Chia Tai TianQing Pharmaceutical GroupTQB3912 tablets

A Clinical Study of TQB3912 Tablets in Patients With Advanced Malignant Tumor

Start: Aug 2023Est. completion: May 2025
Phase 1Completed
NCT05867563Chia Tai TianQing Pharmaceutical GroupTQB2103 for injection

Clinical Trial Evaluating the Safety of the TQB2103 for Injection

Start: Jul 2023Est. completion: May 2025
Phase 1Unknown
NCT03051035Kura OncologyKO-947

First-in-Human Study of KO-947 in Non-Hematological Malignancies

Start: Apr 2017Est. completion: Jun 202061 patients
Phase 1Terminated

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2m ago

Office Administrator

SystImmune
2m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
13m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
16m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
16m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 324 patients
3 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)